Mein Warenkorb

Glucosylceramidase

Glucosylceramidase Molekülinformation

Englischer NameGlucosylceramidaseAnzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel1Target-AliasGlucosylceramidase
Höchste Forschungs- und EntwicklungsphasePhase 1 Clinical
Englischer NameGlucosylceramidase
Target-AliasGlucosylceramidase
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel1
Höchste Forschungs- und EntwicklungsphasePhase 1 Clinical

Glucosylceramidase Produktliste

  • Attribut

    Protein (1)

  • Produktbibliothek

    Online (1)

  • Spezies

    Human (1)

  • Etikett

    His Tag (1)

  • Marker

    Unconjugated (1)

ProduktnummerSpeziesExpressionssystemProduktbeschreibungProteinstrukturReinheitEigenschaftenVorbestellen/Bestellen
GLE-H52H3
Human
HEK293
Human Glucosylceramidase Protein, His Tag
In den Warenkorb legen
Gesamtmenge1
  • 1

Glucosylceramidase Molekülhintergrund

Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramide/GlcCer into free ceramide and glucose. Thereby, it plays a central role in the degradation of complex lipids and the turnover of cellular membranes. Through the production of ceramides,it participates in the PKC-activated salvage pathway of ceramide formation and plays a role in cholesterol metabolism. It may either catalyze the glucosylation of cholesterol, through a transglucosylation reaction that transfers glucose from glucosylceramide to cholesterol. Defects in Glucosylceramidase are the cause of Gaucher disease, also known as glucocerebrosidase deficiency. Gaucher disease is the most prevalent lysosomal storage disease, characterized by accumulation of glucosylceramide in the reticulo-endothelial system. Currently, enzyme replacement therapy is used to treat patients with the disease.

Glucosylceramidase Molekülalias

Glucosylceramidase,GBA,Acid beta-glucosidase,Alglucerase,beta-glucocerebrosidase,D-glucosyl-N-acylsphingosine glucohydrolase,EC 3.2.1.45,GBA,GBA1,GC,GCB,GLUC,glucosidase, beta, acid,glucosidase, beta,acid (includes glucosylceramidase),Glucosylceramidase,I

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
VQ-101VQ-101Phase 1 ClinicalVanqua Bio IncParkinson Disease
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns